Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves Disease
Open Access
- 9 February 2021
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 106 (5), 1325-1332
- https://doi.org/10.1210/clinem/dgab070
Abstract
Context/objective The aim of this study was to examine the effect of statins and other lipid-lowering agents on the development of Graves orbitopathy (GO) in patients with newly diagnosed Graves disease (GD). Methods Our sample included the full adult population of individuals living in Sweden with newly diagnosed GD between 2005 and 2018 (n = 34 894). We compared the GO incidence in statin users (n = 5574) and nonusers (n = 34 409) by applying Cox regression with a time-varying exposure variable. We adjusted for age, sex, and treatment for hyperthyroidism in the multivariate analyses. Results Periods of nonusage lasted for a median of 4.3 years (interquartile range [IQR] 1.2-8.4), whereas periods of usage lasted for a median of 4.7 years (IQR 2.0-8.1). Among statin users, 77.1% had used simvastatin, 28.9% atorvastatin, and 8.2% had used other statins. Statin users were found to be significantly less likely to develop GO. In the main analysis based on the full cohort, the unadjusted hazard ratio (HR) was 0.74 (CI 0.65-0.84, P < .001), whereas full adjustment altered the effect to 0.87 (CI 0.76-1.00, P = .04). The main results were largely driven by men; the fully adjusted HR was 0.78 (CI 0.58-1.04, P = .09) for men and 0.91 (CI 0.79-1.06, P = .24) for women. Lipid-lowering agents other than statins did not exhibit a similar protective effect. Conclusion In newly diagnosed patients with GD, treatment with statins may protect against the development of GO. Statins should be investigated in a clinical trial as a preventive treatment for GO in newly diagnosed patients with GD.Keywords
Funding Information
- SUS fonder and Lundgrens stiftelse
This publication has 35 references indexed in Scilit:
- Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves’ Disease: results of a pilot studyJournal of Endocrinological Investigation, 2020
- Teprotumumab for the Treatment of Active Thyroid Eye DiseaseThe New England Journal of Medicine, 2020
- Insulin-like Growth Factor-I Receptor and Thyroid-Associated OphthalmopathyEndocrine Reviews, 2018
- Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathyJournal of Endocrinological Investigation, 2018
- Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trialThe Lancet Diabetes & Endocrinology, 2018
- Teprotumumab for Thyroid-Associated OphthalmopathyThe New England Journal of Medicine, 2017
- Current Insights into the Pathogenesis of Graves’ OphthalmopathyHormone and Metabolic Research, 2015
- Management plan and delivery of care in Graves’ ophthalmopathy patientsBest Practice & Research Clinical Endocrinology & Metabolism, 2012
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinThe New England Journal of Medicine, 2008
- Epidemiology and Prevention of Graves' OphthalmopathyThyroid®, 2002